|Systematic (IUPAC) name|
|Mol. mass||203.240 g/mol|
5-CT acts as a non-selective, high-affinity full agonist at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5A, and 5-HT7 receptors, as well as at the 5-HT2, 5-HT3, 5-HT6 receptors with lower affinity. It has negligible affinity for the 5-HT1E and 5-HT1F receptors. 5-CT binds strongest to the 5-HT1A receptor and it was once thought to be selective for this site. 5-CT also acts as a serotonin releasing agent.
- Yamada J, Sugimoto Y, Noma T, Yoshikawa T. (1998). "Effects of the non-selective 5-HT receptor agonist, 5-carboxamidotryptamine, on plasma glucose levels in rats.". Eur J Pharmacol. 359 (1): 81–86.
- Wright, CE; Angus, JA (1989). "5-carboxamidotryptamine elicits 5-HT2 and 5-HT3 receptor-mediated cardiovascular responses in the conscious rabbit: evidence for 5-HT release from platelets.". Journal of cardiovascular pharmacology 13 (4): 557–64.
- Glennon RA, Dukat M, Westkaemper RB (2000-01-01). "Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
- Stanton JA, Middlemiss DN, Beer MS. (1996). "Autoradiographic localization of 5-CT-insensitive 5-HT1-like recognition sites in guinea pig and rat brain.". Neuropharmacology. 35 (2): 223–229.
- Thomas, DR; Middlemiss, DN; Taylor, SG; Nelson, P; Brown, AM (1999). "5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors".
- Saxena, PR; Lawang, A (1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives internationales de pharmacodynamie et de therapie 277 (2): 235–52.